GRI Bio, Inc.
GRINASDAQHealthcare● Active
$2.17
+$0.17(+8.50%)
Market Cap$194935
P/E Ratio—
52W High$80.36
52W Low$1.97
GRI Bio, Inc. (GRI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GRI · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$1.61
Est. -$0.91 · -76.9%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS
GRI reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$1.20 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 13, 2026 | -$0.91 | -$1.61 | -76.9% | — | — | — |
| ▲ Q1 FY2026 | Mar 13, 2026 | -$29.27 | -$13.25 | +54.7% | — | — | — |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$31.09 | -$35.85 | -15.3% | $0.01B | — | — |
| — Q3 FY2025 | Aug 14, 2025 | -$1.31 | -$1.31 | +0.0% | $0.02B | — | — |
| ▼ Q2 FY2025 | May 15, 2025 | -$4.11 | -$5.80 | -41.1% | — | — | — |
| — Q4 FY2024 | Dec 16, 2024 | — | -$319.73 | — | — | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.73 | -$11.39 | -1460.3% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$1.20
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$1.61
EPS Est.
-$0.91
EPS Surpr.
-76.9%
Revenue
—
Q1 FY2026
Mar 13, 2026Beat
EPS Actual
-$13.25
EPS Est.
-$29.27
EPS Surpr.
+54.7%
Revenue
—
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$35.85
EPS Est.
-$31.09
EPS Surpr.
-15.3%
Revenue
$0.01B
Q3 FY2025
Aug 14, 2025
EPS Actual
-$1.31
EPS Est.
-$1.31
EPS Surpr.
+0.0%
Revenue
$0.02B
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$5.80
EPS Est.
-$4.11
EPS Surpr.
-41.1%
Revenue
—
Q4 FY2024
Dec 16, 2024
EPS Actual
-$319.73
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$11.39
EPS Est.
-$0.73
EPS Surpr.
-1460.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.16 | $-1.16 | $-1.16 | 1 |
| Q3 FY2027 | $-1.19 | $-1.19 | $-1.19 | 1 |
| Q2 FY2027 | $-1.22 | $-1.22 | $-1.22 | 1 |
| Q1 FY2027 | $-1.25 | $-1.25 | $-1.25 | 1 |
| Q4 FY2026 | $-1.07 | $-1.07 | $-1.07 | 1 |
| Q3 FY2026 | $-1.21 | $-1.08 | $-0.95 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -76.9% | $2.28 | $2.26 | -0.88% |
| ▲ Q1 FY2026 | Mar 13, 2026 | +54.7% | $2.92 | $2.54 | -13.01% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -15.3% | $47.32 | $47.32 | +0.00% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +0.0% | $36.40 | $40.32 | +10.77% |
| ▼ Q2 FY2025 | May 15, 2025 | -41.1% | $41.16 | $40.60 | -1.36% |
| — Q4 FY2024 | Dec 16, 2024 | — | $380.80 | $364.56 | -4.26% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -1460.3% | $418.88 | $456.96 | +9.09% |
| — Q3 FY2024 | Aug 13, 2024 | — | $241.64 | $244.72 | +1.27% |
Q2 FY2026-0.88%
Report Date
May 13, 2026
EPS Beat/Miss
-76.9%
Price Before
$2.28
Price After
$2.26
Q1 FY2026-13.01%
Report Date
Mar 13, 2026
EPS Beat/Miss
+54.7%
Price Before
$2.92
Price After
$2.54
Q4 FY2025+0.00%
Report Date
Nov 14, 2025
EPS Beat/Miss
-15.3%
Price Before
$47.32
Price After
$47.32
Q3 FY2025+10.77%
Report Date
Aug 14, 2025
EPS Beat/Miss
+0.0%
Price Before
$36.40
Price After
$40.32
Q2 FY2025-1.36%
Report Date
May 15, 2025
EPS Beat/Miss
-41.1%
Price Before
$41.16
Price After
$40.60
Q4 FY2024-4.26%
Report Date
Dec 16, 2024
EPS Beat/Miss
—
Price Before
$380.80
Price After
$364.56
Q4 FY2024+9.09%
Report Date
Nov 14, 2024
EPS Beat/Miss
-1460.3%
Price Before
$418.88
Price After
$456.96
Q3 FY2024+1.27%
Report Date
Aug 13, 2024
EPS Beat/Miss
—
Price Before
$241.64
Price After
$244.72
Avg Beat Reaction-1.12%
Avg Miss Reaction+1.71%
Beat Rate2 / 8 quarters
Largest Move-13.01% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GRI ends December
GRI Bio, Inc. (GRI) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-1.61 — missing the analyst consensus of $-0.91 by -76.9%. The next GRI earnings date is expected around September 1, 2026.
Each quarter, investors track GRI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GRI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GRI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GRI earnings · 5 questionsGRI Bio, Inc.'s next earnings report is expected around September 1, 2026. GRI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GRI historically reports after market close (AMC).
GRI earnings datewhen is GRI earningsGRI next earnings datewhen does GRI report earningsGRI earnings calendar
▸ Source: FMP · GRI Bio, Inc. SEC filings · US GAAP · GRI Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026